Internship

2025 Summer Internship

Computational Chemistry & Artificial Intelligence

Confirmed live in the last 24 hours

Arvinas

Arvinas

201-500 employees

Develops therapies targeting disease-causing proteins

No salary listed

No H1B Sponsorship

Remote in USA

Candidates must be located within the U.S.

Category
Applied Machine Learning
Computational Biology
AI & Machine Learning
Biology & Biotech
Required Skills
Python
Git
Requirements
  • A knowledge of organic chemistry at the undergraduate level or higher is required.
  • Proficiency in Python programming required.
  • Experience with a cheminformatics toolkit (RDKit, Openeye, Schrodinger, etc.) is required.
  • Experience using version control (GitHub, GitLab, Bitbucket, etc.) required.
  • Must be able to work effectively in both independent and team contexts.
  • Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship.
Responsibilities
  • Explore generative AI approaches for de novo drug design and synthetic pathway generation.
  • Dive deep into molecular datasets, creating statistically rigorous training, validation, and test sets to optimally retrain generative AI models for real-world prediction and generation tasks.
  • Run generative methods on protein targets of interests and evaluate the quality of the results with an emphasis on synthetic accessibility of the designed molecules.
  • Prepare and present results at an internal Arvinas function at the conclusion of the internship.
Desired Qualifications
  • Experience working on medicinal chemistry projects is desirable.
  • Knowledge of and experience with at least one ML framework (TensorFlow, PyTorch or Keras) is desirable.
  • Knowledge of RNNs, LSTMs, Transformers and LLMs is desirable.
  • Completion of classes in Computational Chemistry, Chemistry, and/or Molecular Biology & Biophysics strongly preferred.
  • Preference for doctoral graduate students nearing degree completion.

Arvinas develops therapies aimed at treating serious diseases caused by harmful proteins. The company uses a special technology called PROTAC® to create protein degraders that work by utilizing the body's natural system to eliminate these unwanted proteins. This approach allows for targeted treatment of conditions like cancer and neurodegenerative disorders. Unlike many other biopharmaceutical companies, Arvinas focuses specifically on the degradation of disease-causing proteins, which sets it apart in the biotechnology field. The goal of Arvinas is to enhance patient outcomes by offering effective treatments that tackle the root causes of debilitating diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

New Haven, Connecticut

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase 3 trial of vepdegestrant enhances Arvinas's leadership in protein degradation.
  • Expansion at Science Park indicates growth and increased R&D capabilities.
  • Strategic executive appointments strengthen financial and commercial operations.

What critics are saying

  • Increased competition in the PROTAC space may impact Arvinas's market share.
  • Potential regulatory scrutiny could delay clinical trials and drug approvals.
  • Dependence on partnerships poses risks if collaborations face challenges.

What makes Arvinas unique

  • Arvinas uses PROTAC technology to target disease-causing proteins for degradation.
  • The company focuses on innovative therapies for cancer and neurodegenerative disorders.
  • Arvinas collaborates with major pharmaceutical companies like Pfizer and Novartis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
PharmiWeb
Mar 12th, 2025
Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefitin a Phase 3 trial –NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population

Investing.com
Jan 10th, 2025
Arvinas outlines 2025 clinical trial plans for breast cancer drug

In a corporate update, Arvinas announced the appointment of Alex Santini as interim Chief Commercial Officer, effective January 17, 2025.

Hartford Business Journal
Dec 18th, 2024
New Haven-based Arvinas to expand Science Park footprint; renews leases

Arvinas said it will also add 1,500 square feet of space at 5 Science Park for a total of 64,000 square feet.

TipRanks
Jun 24th, 2024
Arvinas Appoints Andrew Saik as CFO with Equity Incentives

Arvinas appoints Andrew Saik as CFO with equity incentives.

Yahoo Finance
Jun 17th, 2024
Arvinas Announces Promotions Of Ian Taylor, Ph.D. To President Of Research And Development And Angela Cacace, Ph.D. To Chief Scientific Officer

Arvinas Inc.Ian Taylor, Ph.D.President of Research and Development at Arvinas, Inc.Angela Cacace, Ph.D.Chief Scientific Officer at Arvinas, Inc.NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr